Innovation Pharmaceuticals Inc (IPIX)

[PJ007]

I like the conclusion:

Here we identified the host defense peptide mimetic BRI
as a potential synergizer of CAS. The combination CAS +
BRI shows low cytotoxicity in an in vitro model of human
cells and displayed high efficacy against several human
fungal pathogens in vitro. In addition, the combination CAS
+ BRI was effective in vivo in (i) a murine model of fungal
keratitis and (ii) a chemotherapeutic murine model of
invasive aspergillosis. Taken together, BRI acts
by impacting A. fumigatus calcineurin signaling and the cell
wall integrity pathway converting the fungistatic action of
CAS against A. fumigatus into a fungicidal drug.